Psilocybin trials show poorer control group outcomes compared to SSRIs and esketamine, potentially inflating perceived efficacy due to expectancy bias and functional unblinding. Control group response ...

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the ...

A recent study published in Brain Communications discusses critical questions regarding the evaluation of anti-amyloid immunotherapies for the treatment of Alzheimer’s disease. Study: Key questions ...